{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T22:39:49Z","timestamp":1777070389736,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n Analyze tofacitinib efficacy and safety by background methotrexate (MTX) dose in patients with psoriatic arthritis (PsA).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This post hoc analysis pooled data from two phase III, double-blind trials (OPAL Broaden, NCT01877668; OPAL Beyond, NCT01882439) including patients receiving tofacitinib 5 or 10\u00a0mg twice daily (BID), or placebo, with stable MTX. Efficacy outcomes at month 3 stratified by MTX dose (\u2264 15 month 3 stratified by MTX dose vs >\u200915\u00a0mg\/week) were American College of Rheumatology (ACR)20\/50\/70, Health Assessment Questionnaire-Disability Index (HAQ-DI); Psoriasis Area and Severity Index (PASI)50\/75; change from baseline in HAQ-DI; physician\u2019s global assessment of PsA (PGA-PsA-visual analog scale [VAS]); patient\u2019s global joint and skin assessment (PGJS-VAS), Leeds Enthesitis Index (LEI); and Dactylitis Severity Score (DSS). Safety assessments included adverse events and laboratory parameters.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Five hundred fifty-six patients received tofacitinib 5\u00a0mg BID (\n n<\/jats:italic>\n \u2009=\u2009186), 10\u00a0mg BID (\n n<\/jats:italic>\n \u2009=\u2009178), or placebo (\n n<\/jats:italic>\n \u2009=\u2009192), plus MTX (\u2264\u200915\u00a0mg\/week,\n n<\/jats:italic>\n \u2009=\u2009371; >\u200915\u00a0mg\/week,\n n<\/jats:italic>\n \u2009=\u2009185). At month 3, tofacitinib efficacy was generally greater than placebo. Patients receiving tofacitinib 5\u00a0mg BID demonstrated greater numerical improvements in efficacy outcomes at month 3 with MTX\u2009>\u200915\u00a0mg\/week vs MTX\u2009\u2264\u200915\u00a0mg\/week; patients receiving tofacitinib 10\u00a0mg BID displayed the opposite. The safety profile was generally consistent between groups; headache was associated with MTX\u2009>\u200915\u00a0mg\/week; decreased hemoglobin levels were observed in patients receiving tofacitinib 10\u00a0mg BID and MTX\u2009\u2264\u200915\u00a0mg\/week.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Efficacy of tofacitinib was generally numerically greater than placebo, regardless of MTX dose. Tofacitinib 5\u00a0mg BID was generally more efficacious with MTX\u2009>\u200915\u00a0mg\/week vs\u2009\u2264\u200915\u00a0mg\/week; the opposite was observed for tofacitinib 10\u00a0mg BID. Headache was more frequent with MTX\u2009>\u200915\u00a0mg\/week.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n ClinicalTrials.gov<\/jats:ext-link>\n . Identifier: NCT01877668 (registration: June 14, 2013) and NCT01882439 (registration: June 20, 2013).\n \n \n \n \n \n Key Points<\/jats:bold>\n \u2022 Methotrexate is widely used in the treatment of psoriatic arthritis; however, there are limited data on the impact of varying background methotrexate doses on the efficacy and safety of Janus kinase inhibitors in patients with psoriatic arthritis.<\/jats:italic>\n \u2022 This<\/jats:italic>\n post hoc\n analysis assessed the impact of background methotrexate dose (\u2264 15 or\u2009>\u200915\u00a0mg\/week) on tofacitinib efficacy and safety in patients with psoriatic arthritis.<\/jats:italic>\n \u2022 Results indicated that tofacitinib efficacy was generally numerically greater than placebo, regardless of methotrexate dose. Tofacitinib 5\u00a0mg twice daily, in combination with a higher dose of background methotrexate, was more efficacious compared with a lower dose of background methotrexate; the opposite was observed for tofacitinib 10\u00a0mg twice daily.<\/jats:italic>\n \u2022 Headache was more frequent with the higher methotrexate dose. Data should be interpreted with caution due to the small sample sizes.<\/jats:italic>\n <\/jats:td>\n <\/jats:tr>\n <\/jats:tbody>\n <\/jats:table>\n <\/jats:table-wrap>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s10067-021-05894-2","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T09:05:37Z","timestamp":1631437537000},"page":"499-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials"],"prefix":"10.1007","volume":"41","author":[{"given":"Alan J.","family":"Kivitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valderilio F.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-7685","authenticated-orcid":false,"given":"Liza","family":"Takiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"issue":"10","key":"5894_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957\u2013970","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"5894_CR2","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5894_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","volume":"68","author":"DD Gladman","year":"2009","unstructured":"Gladman DD et al (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68(7):1131\u20131135","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5894_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3899\/jrheum.140021","volume":"41","author":"M Haroon","year":"2014","unstructured":"Haroon M et al (2014) High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 41(7):1357\u20131365","journal-title":"J Rheumatol"},{"issue":"3","key":"5894_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/ker349","volume":"51","author":"VM Bhole","year":"2012","unstructured":"Bhole VM et al (2012) Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 51(3):552\u2013556","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"5894_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41(4):545\u2013568","journal-title":"Rheum Dis Clin N Am"},{"issue":"5","key":"5894_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ et al (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol 69(5):729\u2013735","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"5894_CR8","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10067-014-2651-x","volume":"33","author":"HM Ficco","year":"2014","unstructured":"Ficco HM, Citera G, Cocco JA (2014) Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clin Rheumatol 33(10):1489\u20131493","journal-title":"Clin Rheumatol"},{"issue":"3","key":"5894_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L et al (2016) European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499\u2013510","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5894_CR10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060\u20131071","journal-title":"Arthritis Rheumatol"},{"issue":"5 Suppl 61","key":"5894_CR11","first-page":"S9","volume":"28","author":"FF Coury","year":"2010","unstructured":"Coury FF, Weinblatt ME (2010) Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis. Clin Exp Rheumatol 28(5 Suppl 61):S9\u2013S12","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5894_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","volume":"60","author":"RE Kalb","year":"2009","unstructured":"Kalb RE et al (2009) Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference. J Am Acad Dermatol 60(5):824\u2013837","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"5894_CR13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ et al (2019) Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 71(7):1112\u20131124","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"5894_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/annrheumdis-2012-202959","volume":"73","author":"L Eder","year":"2014","unstructured":"Eder L et al (2014) Tumour necrosis factor \u03b1 blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis 73(6):1007\u20131011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5894_CR15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51(8):1368\u20131377","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5894_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3899\/jrheum.150614","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates LC, Helliwell PS (2016) Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol 43(2):356\u2013361","journal-title":"J Rheumatol"},{"key":"5894_CR17","unstructured":"Pfizer Inc Xeljanz\u00ae (tofacitinib): highlights of prescribing information (2019)"},{"issue":"16","key":"5894_CR18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537\u20131550","journal-title":"N Engl J Med"},{"issue":"16","key":"5894_CR19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D et al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"3","key":"5894_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","volume":"7","author":"P Nash","year":"2020","unstructured":"Nash P et al (2020) Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study. Rheumatol Ther 7(3):553\u2013580","journal-title":"Rheumatol Ther"},{"issue":"8","key":"5894_CR21","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.37765\/ajmc.2020.44075","volume":"26","author":"EJ Maksabedian Hernandez","year":"2020","unstructured":"Maksabedian Hernandez EJ et al (2020) Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-na\u00efve patients. Am J Manag Care 26(8):e252\u2013e257","journal-title":"Am J Manag Care"},{"issue":"6","key":"5894_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3899\/jrheum.151290","volume":"43","author":"B Combe","year":"2016","unstructured":"Combe B et al (2016) Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol 43(6):1063\u20131067","journal-title":"J Rheumatol"},{"issue":"1","key":"5894_CR23","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","volume":"1","author":"PJ Mease","year":"2015","unstructured":"Mease PJ et al (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open 1(1):e000181","journal-title":"RMD Open"},{"issue":"1","key":"5894_CR24","doi-asserted-by":"publisher","first-page":"e000186","DOI":"10.1136\/rmdopen-2015-000186","volume":"2","author":"G Gallo","year":"2016","unstructured":"Gallo G et al (2016) Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage. RMD Open 2(1):e000186","journal-title":"RMD Open"},{"issue":"1","key":"5894_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10067-016-3436-1","volume":"36","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R et al (2017) Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol 36(1):15\u201324","journal-title":"Clin Rheumatol"},{"issue":"5","key":"5894_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/14397595.2018.1553489","volume":"29","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T et al (2019) Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post hoc analysis of clinical trial data. Mod Rheumatol 29(5):756\u2013766","journal-title":"Mod Rheumatol"},{"issue":"8","key":"5894_CR27","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5894_CR28","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ et al (2011) Minimally important difference of health assessment questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 38(11):2461\u20132465","journal-title":"J Rheumatol"},{"issue":"6","key":"5894_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","volume":"39","author":"P Emery","year":"2000","unstructured":"Emery P et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39(6):655\u2013665","journal-title":"Rheumatology (Oxford)"},{"issue":"25","key":"5894_CR30","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370(25):2377\u20132386","journal-title":"N Engl J Med"},{"issue":"1","key":"5894_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.2008.101378","volume":"69","author":"JR Curtis","year":"2010","unstructured":"Curtis JR et al (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide. Ann Rheum Dis 69(1):43\u201347","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 61","key":"5894_CR32","first-page":"S132","volume":"28","author":"A Ceponis","year":"2010","unstructured":"Ceponis A, Kavanaugh A (2010) Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 28(5 Suppl 61):S132\u2013S137","journal-title":"Clin Exp Rheumatol"},{"key":"5894_CR33","unstructured":"European Medicines Agency Xeljanz (tofacitinib citrate): summary of product characteristics (2020)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05894-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T12:54:16Z","timestamp":1699448056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05894-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5894"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05894-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740807180.793588644","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,12]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All persons gave their informed consent prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AJK has been a consultant for AbbVie, Genentech, Genzyme, Janssen, Novartis, Pfizer Inc., Sanofi-Regeneron, and UCB and has been involved in speakers\u2019 bureaus for Celgene, Genentech, Genzyme, Horizon, Novartis, Pfizer Inc., and Sanofi-Regeneron. OF has received research grants from AbbVie, Bristol-Myers Squibb, Novartis, and Pfizer Inc. and has been a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc., and UCB. PN has received research grants and honoraria for lectures and advice on behalf of AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Roche, Sanofi, Pfizer Inc., and UCB and has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer Inc., Sun Pharma, and UCB. SP has been involved in speakers\u2019 bureaus for Celgene and Novartis. VFA has been a consultant for AbbVie, Eli Lilly, Genentech, GSK, Pfizer Inc., and UCB and has been involved in speakers\u2019 bureaus for AbbVie, Janssen, Merck-Serono, Novartis, Pfizer Inc., and Sanofi. CW and LT are employees and shareholders of Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}